Crescita Therapeutics Inc.
CRRTF
$0.36
$0.01273.66%
OTC PK
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 82.80% | -50.02% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 82.80% | -50.02% | |||
| Cost of Revenue | 39.54% | -55.32% | |||
| Gross Profit | 127.11% | -43.10% | |||
| SG&A Expenses | 22.60% | -13.28% | |||
| Depreciation & Amortization | 3.70% | -5.64% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 27.43% | -36.31% | |||
| Operating Income | 156.95% | -634.86% | |||
| Income Before Tax | 188.82% | -416.63% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 188.82% | -461.28% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 188.82% | -461.28% | |||
| EBIT | 156.95% | -634.86% | |||
| EBITDA | 236.94% | -831.85% | |||
| EPS Basic | 189.44% | -459.02% | |||
| Normalized Basic EPS | 189.20% | -475.68% | |||
| EPS Diluted | 184.75% | -459.02% | |||
| Normalized Diluted EPS | 188.73% | -475.68% | |||
| Average Basic Shares Outstanding | -0.50% | -0.49% | |||
| Average Diluted Shares Outstanding | 0.05% | -0.49% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||